(ISSN 2577-5804)
Welcome to the new academic journal OBM Hepatology and Gastroenterology. Recent progress in understanding liver, biliary, pancreatic and gastro-intestinal diseases and their treatments has been observed in the world. OBM Hepatology and Gastroenterology publishes interesting and informative reviews, original articles, and invaluable case reports in this area. We also publish basic research as well as clinical research.
Hepatitis A virus (HAV), HBV, HCV, HDV, and HEV are still a serious issue worldwide. Treatments on these viruses have recently improved. However, liver fibrosis, cirrhosis and hepatocellular carcinoma are still critical conditions. We focus on all of these liver diseases. We also focus on broad-spectrum of gastro-intestinal diseases in this journal.
Please accept our special thanks for choosing to publish in the OBM Hepatology and Gastroenterology. We are looking forward to your submissions for OBM Hepatology and Gastroenterology.
Archiving: full-text archived in CLOCKSS.
Special Issue
Exploring Novel Treatment Options for Liver Fibrosis: Can Anti-Angiogenics Succeed？
Submission Deadline: March 31, 2019 (Open) Submit Now
Guest Editor
Matthias Bartneck
Department of Medicine III, Medical Faculty, RWTH Aachen, Germany
E-Mail: [email protected]
Website: www.bartneck-lab.ukaachen.de
ORC ID: 0000-0003-1516-9610
Research gate: www.researchgate.net/profile/Matthias_Bartneck
Research Interests: Innate immunity; cytokines; macrophages; hepatic stellate cells; cancer cells; liver diseases; cellular immunology; nanomedicine; theranostics
About This Topic
Liver fibrosis is promoted by sustained liver injury which frequently leads to portal hypertension which is accompanied by angiogenic processes. Chronic liver diseases represent a serious global health concern and novel strategies to modulate tissue regeneration are urgently needed. The highly motile immune cells represent a valueable target of exploratory therapies, due to their crosstalk with other cell types such as hepatic stellate cells which generate matrix proteins, and with endothelial cells responsible for blood vessel formation. Three types of drugs compete for therapeutic success in fibrosis treatment: 1) nanomedicines, which have enriched the field of drug delivery, specifically by reducing systemic spreading of drugs; 2) next generation biologicals such as bispecific antibodies which may strongly broaden the options to modulate cellular functionality, while 3) small molecules represent a cost-efficient and safe option.
Planned Papers
Title：Zinc in liver fibrosis
Author: Kurt Grüngreiff
Affiliation: Clinic of Gastroenterology, City Hospital, Magdeburg, 39130 Magdeburg, Birkenallee 34, Germany
Title: The Autotaxin - Lysophosphatidic Acid axis as a novel therapeutic target for liver fibrosis
Authors: Richell Booijink 1, Ruchi Bansal 1, 2
Affiliation:
1. Department of Biomaterials Science and Technology, Technical Medical Centre, Faculty of Science and Technology, University of Twente, Enschede, the Netherlands
2. Department of Pharmacokinetics, Toxicology and Targeting, Groningen Research Institute of Pharmacy, University of Groningen, the Netherlands
Publication
Marta Ramirez, Mercedes Fernandez
Received: February 25, 2019; Published: July 31, 2019; doi:10.21926/obm.hg.1903030
Richell Booijink, Ruchi Bansal
Received: March 27, 2019; Published: June 21, 2019; doi:10.21926/obm.hg.1902024
Kurt Grüngreiff , Thomas Gottstein, Dirk Reinhold
Received: March 15, 2019; Published: June 13, 2019; doi:10.21926/obm.hg.1902023
Athina Chasapi , Konstantinos Balampanis, Anna Tanoglidi, Eleni Kourea, George I. Lambrou, Vaia Lambadiari, Fotios Kalfarentzos, Erifili Hatziagelaki, Maria Melachrinou, Georgia Sotiropoulou-Bonikou
Received: January 28, 2019; Published: May 22, 2019; doi:10.21926/obm.hg.1902020
Ramareddy V Guntaka
Received: December 20, 2018; Published: March 13, 2019; doi:10.21926/obm.hg.1901014
TOP